| Companies sponsors |
Ipsen (cabozantinib) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| Patient carer groups |
Black Health Agency for Equality |
| |
Bowel Cancer UK |
| |
Cancer Black Care |
| |
Cancer Equality |
| |
Cancer52 |
| |
Gist Cancer UK |
| |
Guts UK |
| |
Helen Rollason Cancer Charity |
| |
Independent Cancer Patients Voice |
| |
Insulinoma Support Network |
| |
Macmillan Cancer Support |
| |
Maggie’s Centres |
| |
Marie Curie |
| |
Neuroendocrine Cancer UK |
| |
OG Support |
| |
Pancreatic Cancer Action |
| |
Pancreatic Cancer UK |
| |
South Asian Health Foundation |
| |
Specialised Healthcare Alliance |
| |
Tenovus Cancer Care |
| Professional groups |
Association of Cancer Physicians |
| |
British Geriatrics Society |
| |
British Nuclear Medicine Society |
| |
British Oncology Pharmacy Association |
| |
British Psychosocial Oncology Society |
| |
British Society of Gastroenterology |
| |
Cancer Research UK |
| |
Royal College of General Practitioners |
| |
Royal College of Nursing |
| |
Royal College of Pathologists |
| |
Royal College of Physicians |
| |
Royal Pharmaceutical Society |
| |
Royal Society of Medicine |
| |
Society for Endocrinology |
| |
UK Acute Oncology Society |
| |
UK Clinical Pharmacy Association |
| |
UKI NETS |
| |
UK Oncology Nursing Society |
| Associated public health groups |
Public Health Wales |
| |
UK Health Security Agency |
| Comparator companies |
Accord Healthcare (5-fluorouracil, temozolomide) |
| |
Amarox (capecitabine) |
| |
Baxter (doxorubicin) |
| |
Dr Reddy’s Laboratories (capecitabine, everolimus, sunitinib) |
| |
Esteve Pharmaceuticals (streptozocin) |
| |
Ethypharm UK (everolimus) |
| |
Glenmark Pharmaceuticals (capecitabine) |
| |
Hospira UK (carboplatin, cisplatin, 5-fluorouracil) |
| |
medac GmBH (doxorubicin, 5-fluorouracil,) |
| |
Merck Sharp & Dohme (temozolomide) |
| |
MSN Laboratories (sunitinib) |
| |
Mylan (sunitinib) |
| |
Neon Healthcare (etoposide |
| |
Novartis (everolimus, lutetium (177Lu) oxodotreotide) |
| |
Pfizer (doxorubicin, sunitinib) |
| |
Piramal Critical Care (sunitinib) |
| |
Sandoz (cisplatin, everolimus, sunitinib) |
| |
Seacross (doxorubicin) |
| |
Sun Pharma (temozolomide) |
| |
Teva Pharma (sunitinib) |
| |
Zentiva (sunitinib) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
Allied Health Professionals Federation |
| |
Board of Community Health Councils in Wales |
| |
British National Formulary |
| |
Care Quality Commission |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
National Association of Primary Care |
| |
National Pharmacy Association |
| |
NHS Confederation |
| |
Scottish Medicines Consortium |
| |
Scottish Society of Gastroenterology |
| |
Welsh Government |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Cochrane Gut |
| |
Cochrane Metabolic & Endocrine Disorders Group |
| |
Genomics England |
| |
MRC Clinical Trials Unit |
| |
National Institute for Health Research |